The Multiple Myeloma Program is one of the leading programs in the country for the diagnosis and treatment of multiple myeloma and is utilized by myeloma patients from around the world. Our interdisciplinary approach to patient care means that patients are seen by a team of treatment specialists with expertise in the care of patients with myeloma and other hematologic malignancies.
The Multiple Myeloma Program at Mount Sinai is a Clinical Research Center with novel drug therapies. The program conducted clinical trials with Lenalidomide and Bortezomib, two novel drugs that are now standard of care. As a result, multiple myeloma patients now have access to highly promising clinical studies and the latest treatment breakthroughs. The Multiple Myeloma Program works cohesively with the Bone Marrow Transplant (BMT) program at Mount Sinai.